chloramphenicol has been researched along with allopurinol in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (28.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Abraham, MH; Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Christensen, LK; Hansen, JM | 1 |
| Sellers, E; Weser, JK | 1 |
| Feller, DR; Gillette, JR; Morita, M | 1 |
| Fabre, J; Herrera, A; Perrin, L; Petitpierre, B; Rudhardt, M | 1 |
| Fabre, J; Perrin, L; Petitpierre, B; Rudhardt, M | 1 |
| Fraunfelder, FT; Meyer, SM | 1 |
| Liu, X; Matsuhashi, T; Nishizawa, Y; Usukura, J; Wakabayashi, T; Wozniak, M | 1 |
| Adachi, K; Antosiewicz, J; Karbowsky, M; Matsuhashi, T; Wakabayashi, T; Wozniak, M | 1 |
| BETHELL, FH; SWANSON, AL; SWENDSEID, ME | 1 |
4 review(s) available for chloramphenicol and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions with oral sulphonylurea hypoglycaemic drugs.
Topics: Allopurinol; Analgesics; Anticoagulants; Chloramphenicol; Chlorpropamide; Disulfiram; Drug Interactions; Ethanol; Glyburide; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Monoamine Oxidase Inhibitors; Novobiocin; Phenylbutazone; Phenytoin; Probenecid; Propranolol; Rifampin; Sulfonamides; Sulfonylurea Compounds; Tolbutamide | 1977 |
Drug interactions with coumarin anticoagulants. 2.
Topics: Allopurinol; Anabolic Agents; Animals; Anti-Bacterial Agents; Anticoagulants; Barbiturates; Chloral Hydrate; Chloramphenicol; Cholestyramine Resin; Clofibrate; Contraceptives, Oral; Coumarins; Dextrothyroxine; Diuretics; Drug Antagonism; Drug Synergism; Ethacrynic Acid; Ethanol; Glucagon; Glucocorticoids; Glutethimide; Humans; Oxyphenbutazone; Phenylbutazone; Quinidine; Quinine; Quinolines; Salicylates; Sulfinpyrazone; Sulfonamides; Thyroid Hormones; Tolbutamide | 1971 |
Ocular toxicology update.
Topics: Adult; Aged; Allopurinol; Carbonic Anhydrase Inhibitors; Chloramphenicol; Eye Diseases; Humans; Ophthalmic Solutions; Phenylephrine; Timolol | 1984 |
21 other study(ies) available for chloramphenicol and allopurinol
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogPoct: a tool for lipophilicity determination in drug discovery.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Solvents | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Reduction of niridazole by rat liver santhine oxidase.
Topics: Adenine; Aerobiosis; Allopurinol; Anaerobiosis; Animals; Anthelmintics; Azaguanine; Chemical Precipitation; Chloramphenicol; Furazolidone; Hydrogen-Ion Concentration; Hypoxanthines; Imidazoles; Ketones; Kinetics; Liver; Male; Milk; NAD; NADP; Nitro Compounds; Nitrofurazone; Nitrophenols; Quaternary Ammonium Compounds; Rats; Sulfates; Thiazoles; Xanthine Oxidase | 1971 |
Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.
Topics: Acenocoumarol; Allopurinol; Chloramphenicol; Chlorpropamide; Clofibrate; Glomerular Filtration Rate; Glomerulonephritis; Half-Life; Humans; Kidney; Kidney Diseases; Probenecid; Pyelonephritis | 1972 |
[Behavior of chlorpropamide in nephropathies in the presence of associated drugs].
Topics: Allopurinol; Chloramphenicol; Chlorpropamide; Chromium Isotopes; Humans; Kidney Diseases; Probenecid | 1972 |
Mechanism of the formation of megamitochondria in the mouse liver induced by chloramphenicol.
Topics: Allopurinol; Animals; Body Weight; Chloramphenicol; Enzyme Inhibitors; Lipid Peroxidation; Liver; Male; Mice; Microscopy, Electron; Mitochondria, Liver; Mitochondrial Swelling; Organ Size; Piperidines; Protein Synthesis Inhibitors; Purine Nucleotides | 1996 |
Suppression of the formation of megamitochondria by scavengers for free radicals.
Topics: Allopurinol; Animals; Body Weight; Chloramphenicol; Coenzymes; Cyclic N-Oxides; Depression, Chemical; Enzyme Inhibitors; Ethanol; Free Radical Scavengers; Hydrazines; Lipid Peroxidation; Male; Malondialdehyde; Membrane Fusion; Mitochondria, Liver; Purines; Rats; Rats, Wistar; Spin Labels; Ubiquinone; Vitamin E; Xanthine Oxidase | 1997 |
Effect of chloramphenicol administration on rat liver xanthine oxidase.
Topics: Animals; Chloramphenicol; Liver; Oxidoreductases; Rats; Xanthine Oxidase | 1953 |